1. Adams HP Jr, Biller J. Classification of subtypes of ischemic stroke: history of the Trial of ORG 10172 in Acute Stroke Treatment classification. Stroke. 2015;46(5):e114-e117. doi:10.1161/STROKEAHA.114.007773
2. Wu S, Sena E, Egan K, Macleod M, Mead G. Edaravone improves functional and structural outcomes in animal models of focal cerebral ischemia: a systematic review. Int J Stroke. 2014;9(1):101-106. doi:10.1111/ijs.12163
3. Rabinstein AA. Update on treatment of acute ischemic stroke. Continuum (Minneap Minn). 2020;26(2):268-286. doi:10.1212/CON.0000000000000840
4. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke. Stroke. 2019;50: e344-e418. doi:10.1161/STR.0000000000000211
5. Lin L, Wang X, Yu Z. Ischemia-reperfusion injury in the brain: mechanisms and potential therapeutic strategies. Biochem Pharmacol (Los Angel). 2016;5(4):1000213. doi:10.4172/2167-0501.1000213
6. Jurcau A, Simion A. Neuroinflammation in cerebral ischemia and ischemia/reperfusion injuries. Int J Mol Sci. 2021;23(1):267.
7. Wu L, Xiong X, Wu X, et al. Targeting oxidative stress and inflammation to prevent ischemia-reperfusion injury. Front Mol Neurosci. 2020;13:28. doi:10.3389/fnmol.2020.00028
8. Bredt DS, Snyder SH. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc Natl Acad Sci U S A. 1989;86(22):9030-9033. doi:10.1073/pnas.86.22.9030
9. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007;87(1):315-424. doi:10.1152/physrev.00029.2006
10. Imai H, Graham DI, Masayasu H, Macrae IM. Antioxidant ebselen reduces oxidative damage in focal cerebral ischemia. Free Radic Biol Med. 2003;34(1):56-63. doi:10.1016/s0891-5849(02)01180-2
11. Uchida K. Role of reactive aldehyde in cardiovascular diseases. Free Radic Biol Med. 2000;28(12):1685-1696. doi:10.1016/s0891-5849(00)00226-4
12. Giera M, Lingeman H, Niessen WMA. Recent advancements in the LC- and GC-based analysis of malondialdehyde (MDA): a brief overview. Chromatographia. 2012;75(9-10):433-440. doi:10.1007/s10337-012-2237-1
13. Del Rio D, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis. 2005;15(4):316-328. doi:10.1016/j.numecd.2005.05.003
14. Pryor WA, Stanley JP. A suggested mechanism for the production of malonaldehyde during the autoxidation of polyunsaturated fatty acids. J Org Chem. 1975;40(24):3615-3617. doi:10.1021/jo00912a038
15. Drieu A, Levard D, Vivien D, et al. Anti-inflammatory treatments for stroke: from bench to bedside. Ther Adv Neurol Disord. 2018;11: 1756286418789854. doi:10.1177/1756286418789854
16. Jurcau A, Ardelean IA. Molecular pathophysiological mechanisms of ischemia/reperfusion injuries after recanalization therapy for acute ischemic stroke. J Integr Neurosci. 2021;20(3):727-744. doi:10.31083/j.jin2003078
17. Jayaraj RL, Azimullah S, Beiram R, Jalal FY, Rosenberg GA. Neuroinflammation: friend and foe for ischemic stroke. J Neuroinflammation. 2019;16(1):142. doi:10.1186/s12974-019-1516-2
18. Lapchak PA, Araujo DM. Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin Emerg Drugs. 2007;12(1):97-112. doi:10.1517/14728214.12.1.97
19. Kono H, Woods CG, Maki A, et al. Electron spin resonance and spin trapping technique provide direct evidence that edaravone prevents acute ischemia-reperfusion injury of the liver by limiting free radical-mediated tissue damage. Free Radic Res. 2006;40(6):579-588. doi:10.1080/10715760600606374
20. Shichinohe H, Kuroda S, Yasuda H, et al. Neuroprotective effects of the free radical scavenger edaravone (MCI-186) in mice permanent focal brain ischemia. Brain Res. 2004;1029(2):200-206. doi:10.1016/j.brainres.2004.09.055
21. Banno M, Mizuno T, Kato H, et al. The radical scavenger edaravone prevents oxidative neurotoxicity induced by peroxynitrite and activated microglia. Neuropharmacology. 2005;48(2):283-290. doi:10.1016/j.neuropharm.2004.10.002
22. Higashi Y. Edaravone for the treatment of acute cerebral infarction: role of endothelium-derived nitric oxide and oxidative stress. Expert Opin Pharmacother. 2009;10(2):323-331. doi:10.1517/14656560802636888
23. Kawasaki H, Ito Y, Kitabayashi C, et al. Effects of edaravone on nitric oxide, hydroxyl radicals and neuronal nitric oxide synthase during cerebral ischemia and reperfusion in mice. J Stroke Cerebrovasc Dis. 2020;29(3):104531. doi:10.1016/j.jstrokecerebrovasdis.2019.104531
24. Zhang N, Komine-Kobayashi M, Tanaka R, et al. Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke. 2005; 36(10):2220-2225. doi:10.1161/01.STR.0000182241.07096.06
25. Arrigoni O, De Tullio MC. Ascorbic acid: much more than just an antioxidant. Biochim Biophys Acta. 2002;1569(1-3):1-9. doi:10.1016/s0304-4165(01)00235-5
26. Ranjan A, Theodore D, Haran RP, Chandy MJ. Ascorbic acid and focal cerebral ischaemia in a primate model. Acta Neurochir (Wien). 1993; 123(1-2):87-91. doi:10.1007/BF01476291
27. Frei B, England L, Ames BN. Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci U S A. 1989;86(16):6377-6381. doi:10.1073/pnas.86.16.6377
28. Tanaka M. Pharmacological and clinical profile of the free radical scavenger edaravone as a neuroprotective agent. Nihon Yakurigaku Zasshi. 2002;119(5):301-308. doi:10.1254/fpj.119.301
29. Oishi R, Itoh Y, Nishibori M, Watanabe T, Nishi H, Saeki K. Effect of MCI-186 on ischemia-induced changes in monoamine metabolism in rat brain. Stroke. 1989;20(11):1557-1564. doi:10.1161/01.str.20.11.1557
30. Zhang G, Sun Y, Wang Y, et al. Local administration of lactic acid and a low dose of the free radical scavenger edaravone alleviates myocardial reperfusion injury in rats. J Cardiovasc Pharmacol. 2013;62(4):369-378. doi:10.1097/01.fjc.0000432860.48345.9d
31. Spector R. Dehydroascorbic acid for the treatment of acute ischemic stroke. Med Hypotheses. 2016;89:32-36. doi:10.1016/j.mehy.2016.01.021
32. Henry PT, Chandy MJ. Effect of ascorbic acid on infarct size in experimental focal cerebral ischaemia and reperfusion in a primate model. Acta Neurochir (Wien). 1998;140(9):977-980. doi:10.1007/s007010050201
33. Li S, Bian L, Fu X, et al. Gastrodin pretreatment alleviates rat brain injury caused by cerebral ischemic-reperfusion. Brain Res. 2019;1712: 207-216. doi:10.1016/j.brainres.2019.02.006
34. Suzuki J, Fujimoto S, Mizoi K, Oba M. The protective effect of combined administration of anti-oxidants and perfluorochemicals on cerebral ischemia. Stroke. 1984;15(4):672-679. doi:10.1161/01.str.15.4.672
35. Salman E, Bayraktaroglu M, Dogan OV, Yorukoglu Y, Yucel E, Kosebalaban S. Use of ascorbic acid in open heart surgery as an oxygen free radical scavenger. Turk Gogus Kalp Damar Cerrahisi Derg. 1994;2: 216-220.
36. Kumar A, Aakriti, Gupta V. A review on animal models of stroke: an update. Brain Res Bull. 2016;122:35-44. doi:10.1016/j.brainresbull.2016.02.016
37. Zeng L, Hu S, Zeng L, et al. Animal models of ischemic stroke with different forms of middle cerebral artery occlusion.Brain Sci. 2023; 13(7):1007. doi:10.3390/brainsci13071007
38. Jurcau A, Ardelean AI. Oxidative stress in ischemia/reperfusion injuries following acute ischemic stroke. Biomedicines. 2022;10(3):574. doi:10.3390/biomedicines10030574
39. Yang M, Liu B, Chen B, Shen Y, Liu G. Cerebral ischemia-reperfusion injury: mechanisms and promising therapies. Front Pharmacol. 2025; 16:1613464. doi:10.3389/fphar.2025.1613464